|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chiapponi C, Hartmann MJM, Schmidt M,
Faust M, Schultheis AM, Bruns CJ and Alakus H: Radioiodine
refractory follicular thyroid cancer and surgery for cervical
relapse. Cancers (Basel). 13:6230–6240. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Luvhengo TE, Bombil I, Mokhtari A, Moeng
MS, Demetriou D, Sanders C and Dlamini Z: Multi-omics and
management of follicular carcinoma of the thyroid. Biomedicines.
11:12172023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vuong HG, Le MK, Hassell L, Kondo T and
Kakudo K: The differences in distant metastatic patterns and their
corresponding survival between thyroid cancer subtypes. Head Neck.
44:926–932. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American thyroid association management
guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The American thyroid association
guidelines task force on thyroid nodules and differentiated thyroid
cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dong Y, Zhong J and Dong L: The role of
decorin in autoimmune and inflammatory diseases. J Immunol Res.
2022:12833832022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu X, Villodre ES, Larson R, Rahal OM,
Wang X, Gong Y, Song J, Krishnamurthy S, Ueno NT, Tripathy D, et
al: Decorin-mediated suppression of tumorigenesis, invasion, and
metastasis in inflammatory breast cancer. Commun Biol. 4:722021.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mondal DK, Xie C, Pascal GJ, Buraschi S
and Iozzo RV: Decorin suppresses tumor lymphangiogenesis: A
mechanism to curtail cancer progression. Proc Natl Acad Sci USA.
121:e23177601212024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Horváth Z, Kovalszky I, Fullár A, Kiss K,
Schaff Z, Iozzo RV and Baghy K: Decorin deficiency promotes hepatic
carcinogenesis. Matrix Biol. 35:194–205. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Reszegi A, Horváth Z, Fehér H, Wichmann B,
Tátrai P, Kovalszky I and Baghy K: Protective role of decorin in
primary hepatocellular carcinoma. Front Oncol. 10:6452020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bi X, Pohl NM, Qian Z, Yang GR, Gou Y,
Guzman G, Kajdacsy-Balla A, Iozzo RV and Yang W: Decorin-mediated
inhibition of colorectal cancer growth and migration is associated
with E-cadherin in vitro and in mice. Carcinogenesis. 33:326–330.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reszegi A, Horváth Z, Karászi K, Regős E,
Postniková V, Tátrai P, Kiss A, Schaff Z, Kovalszky I and Baghy K:
The protective role of decorin in hepatic metastasis of colorectal
carcinoma. Biomolecules. 10:11992020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Arnaldi LA, Borra RC, Maciel RM and
Cerutti JM: Gene expression profiles reveal that DCN, DIO1, and
DIO2 are underexpressed in benign and malignant thyroid tumors.
Thyroid. 15:210–221. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin Q, Ma Y and Chen P: Identification of
potential biomarkers in follicular thyroid carcinoma:
Bioinformatics and immunohistochemical analyses. Oncologie.
26:311–322. 2024. View Article : Google Scholar
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−delta delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Phay JE and Ringel MD: Metastatic
mechanisms in follicular cell-derived thyroid cancer. Endocr Relat
Cancer. 20:R307–R319. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Karapanou O, Simeakis G, Vlassopoulou B,
Alevizaki M and Saltiki K: Advanced RAI-refractory thyroid cancer:
An update on treatment perspectives. Endocr Relat Cancer.
29:R57–R66. 2022. View Article : Google Scholar : PubMed/NCBI
|
